2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Exploring the self-image of women with Parkinson’s
There is a fundamental gap in knowledge of how Parkinson’s manifests and affects women. The Parkinson’s advocate group, PD Avengers and a collection of women living with Parkinson’s have joined Fox Insight, a surveying platform created by the Michael J Fox Foundation, to design a…
2023: research highlights for the year ahead
Cure Parkinson’s is looking forward to an eventful 12 months – here we provide a summary of what’s on the horizon.
Research Update Meeting Spring 2023 – recorded to watch again
Our popular and much-awaited research update meeting brought together two leading clinicians to report on their individual area of expertise for Parkinson’s. It’s available to watch again!
USD $4.5 million co-funding agreement for Parkinson’s research renewed
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports collaborative Parkinson’s clinical trials, has been renewed for a further three years.
The role of faulty cell protein in Parkinson’s
A process called m6A mRNA methylation is reduced in people with Parkinson’s. Research is underway to develop drugs that can improve this protein production process.